How CVS’s Pharmacy Benefits Management Drives Higher Drug Prices for Patients

The column recounts a prolonged dispute with CVS Caremark after a physician ordered a 90-day mail-order supply of a kidney-stone preventive drug. CVS consistently delivered only a 30-day quantity, attaching a vague notice that the prescription plan limited coverage. Over a year of inquiries, including assistance from the District of Columbia’s Office of Health Care Ombudsman, the author discovered that a third-party data vendor, Medispan, labels the medication as non-maintenance, enforcing a 30-day limit under the CareFirst plan.

CVS offered an exceptions process administered by the insurer, but failed to provide clear guidance initially. Comparing prices, the writer found cash options through Cost Plus Drugs and Pharmacy Checker were dramatically cheaper than CVS’s charge. CVS defended the disparity by citing plan- and pharmacy-specific member costs, yet the author contends that PBMs exploit such complexities to boost pharmacy profits while capping insurance-related earnings under Obamacare rules. The piece urges patients to explore cash-pay alternatives to avoid inflated costs and administrative hurdles.